Join the club for FREE to access the whole archive and other member benefits.

Gene editing lowered blood level cholesterol and triglycerides in monkeys


Key points from article :

Scientists have disabled two genes in monkeys that raise the risk for heart disease.

One is PCSK9, which helps regulate levels of LDL cholesterol.

The other is ANGPTL3, part of the system regulating triglyceride, a type of blood fat.

Both are active in liver, which is where cholesterol and triglycerides are produced.

People who inherit mutations that destroyed the genes’ function do not get heart disease.

The medicine consists of two pieces of RNA — a gene editor and a tiny guide.

Not only did the system work in 13 monkeys, but it appeared that every liver cell was edited.

The monkeys’ LDL levels dropped by 59 percent within two weeks.

The ANGPTL3 gene editing led to a 64 percent decline in triglyceride levels.

First study to use the pencil-and-eraser type gene editing in primates for a very common disease.

But much too soon to say if it will be safe and long-lasting.

Research from Verve Therapeutics; not yet been peer-reviewed or published.

Could prevent not only the complications but the heart disease per se in the future

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Collaborative organization that brings academics of various disciplines in the scientific community together


Professor in Pediatrics


Nonprofit life science research organization


Professor of Biomedical Science

Health Organisation

Largest teaching hospital of Harvard Medical School located in Boston


Professor, Director of the Lipid Clinic, The University of Chicago


Physician scientist, human geneticist and professor at Harvard Medical School.


Public Research university.


Public land-grant research university


Biotechnology company